NR1H4 and metabolic dysfunction-associated steatohepatitis: Indeed, recent literatures have highlighted FXR as a potential therapeutic target for different metabolic diseases, such as parenteral nutrition associated cholestasis [18], vertical sleeve gastrectomy [19], and more commonly nonalcoholic steatohepatitis (NASH) [20], [21], while only limited treatment options are currently available for these diseases.